Clinical Study of Personalized Neoantigen Peptide Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer
Latest Information Update: 06 Dec 2022
At a glance
- Drugs HJ N 001 (Primary) ; Angiogenesis inhibitors; Vascular endothelial growth factor receptor antagonists
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Jul 2020 New trial record